- Internal Medicine
Clinical Assistant Professor, Medicine - Primary Care and Population Health
Medical Informatics Director for Primary Care and Population Health, Stanford Health Care (2020 - Present)
Board Certification: American Board of Preventive Medicine, Clinical Informatics (2022)
Residency: Stanford University Internal Medicine Residency (2017) CA
Board Certification: American Board of Internal Medicine, Internal Medicine (2017)
Medical Education: Northwestern University Feinberg School of Medicine (2014) IL
Independent Studies (2)
- Graduate Research
MED 399 (Win)
- Undergraduate Research
MED 199 (Win)
- Graduate Research
Predicting Avoidable Health Care Utilization: Practical Considerations for Artificial Intelligence/Machine Learning Models in Population Health.
Mayo Clinic proceedings
2022; 97 (4): 653-657
View details for DOI 10.1016/j.mayocp.2021.11.039
View details for PubMedID 35379419
IT TAKES A VILLAGE: COMPARATIVE ANALYSIS OF STRATEGIES TO IMPROVE PROVIDER ENGAGEMENT FOR WEIGHT MANAGEMENT AT AN ACADEMIC MEDICAL CENTER
SPRINGER. 2020: S667–S668
View details for Web of Science ID 000567143602165
"MAKING A LIST AND CHECKING IT TWICE": A HIGH BLOOD PRESSURE ADVISORY IN PRIMARY CARE
SPRINGER. 2020: S702
View details for Web of Science ID 000567143602227
A Practical Approach to Low-Dose Aspirin for Primary Prevention.
View details for DOI 10.1001/jama.2019.8388
View details for PubMedID 31251325
UTILIZATION OF ELECTRONIC HEALTH RECORD PREFERENCE LISTS TO IMPROVE EFFICIENCY, CONSISTENCY AND SATISFACTION AMONG PROVIDERS IN THE AMBULATORY CARE SETTING
SPRINGER. 2018: S837–S838
View details for Web of Science ID 000442641404248
Patterns of Systolic Blood Pressure Control in the United States, 2016.
Journal of general internal medicine
View details for PubMedID 29679225
Current Trends of Hypertension Treatment in the United States.
American journal of hypertension
To examine current patterns of hypertension (HTN) treatment in the United States, including blood pressure (BP) control, prevalence of different antihypertensive agents, and variations in treatment associated with patient and physician characteristics.We used data from the National Disease and Therapeutic Index (NDTI), a nationally representative physician survey produced by QuintilesIMS. We selected patients with a diagnosis of HTN and identified those prescribed antihypertensive therapies. We analyzed the type of antihypertensive agents prescribed. Extent of BP control, and associated patient and physician characteristics. We calculated 95% confidence intervals that accounted for the multistage NDTI sampling design.Among those treated for HTN in 2014, BP control varied: systolic BP (SBP) ≥160 (15%) vs. SBP 150-159 (9%) vs. SBP 140-149 (19%) vs. SBP 130-139 (26%) vs. SBP <130 (32%). Of those treated for HTN, 29% used of angiotensin-converting enzyme inhibitors (ACEIs); 24%, thiazide-like diuretics; 22%, angiotensin receptor blockers (ARBs), 21%, calcium-channel blockers (CCBs); and 19% beta-blockers. Newer drugs had very limited uptake; no drugs approved after 2002 were used in more than 5% of patients. Selection of agents varied only modestly by patient and physician characteristics.The treatment of HTN in 2014 predominantly involved older medications in 5 major classes of drugs: ACEIs, thiazide diuretics, ARBs, CCBs, and beta-blockers. Selection of antihypertensive agents showed limited variation by age, gender, race, and insurance type. Although 58% of treated patients had SBP <140, 24% had poorly controlled HTN with SBP ≥150, indicating the need for improved treatment.
View details for DOI 10.1093/ajh/hpx085
View details for PubMedID 28531239
Community health center patients' response to and beliefs about outreach promoting clinical preventive services.
Preventive medicine reports
2017; 5: 71-74
We sought community health center (CHC) patients' feedback regarding an outreach intervention promoting primary prevention of cardiovascular disease to patients at increased risk. We performed a telephone survey that assessed whether patients recalled receiving the intervention, what actions occurred in response to the intervention, and patient attitudes regarding receipt of preventive service messages from their CHC. Participants (n = 80) were 89% male, and 59% were black. Among the 88% of respondents who reported a healthcare visit, 84% reported a discussion about cholesterol or heart disease risk with their provider, of these 44% reported a statin was recommended and 89% reported currently taking it. Participants reported high acceptability of receiving preventive service messages, but were less likely to agree that they wanted to receive preventive service messages via text or email compared to other modes of contact. Our results show that outreach programs to promote indicated preventive services were viewed positively by this patient group. We also identified areas where the CVD prevention program may have lost effectiveness.
View details for PubMedID 27957409
View details for PubMedCentralID PMC5148778
Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers Randomized Trial
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
2015; 8 (6): 560-566
Many eligible primary cardiovascular disease prevention candidates are not treated with statins. Electronic health record data can identify patients with increased cardiovascular disease risk.We performed a pragmatic randomized controlled trial at community health centers in 2 states. Participants were men aged ≥35 years and women ≥45 years, without cardiovascular disease or diabetes mellitus, and with a 10-year risk of coronary heart disease of at least 10%. The intervention group received telephone and mailed outreach, individualized based on patients' cardiovascular disease risk and uncontrolled risk factors, provided by lay health workers. Main outcomes included: documented discussion of medication treatment for cholesterol with a primary care clinician, receipt of statin prescription within 6 months, and low-density lipoprotein (LDL)-cholesterol repeated and at least 30 mg/dL lower than baseline within 1 year. Six hundred forty-six participants (328 and 318 in the intervention and control groups, respectively) were included. At 6 months, 26.8% of intervention and 11.6% of control patients had discussed cholesterol treatment with a primary care clinician (odds ratio, 2.79; [95% confidence interval, 2.25-3.46]). Statin prescribing occurred for 10.1% in the intervention group and 6.0% in the control group (odds ratio, 1.76; [95% confidence interval, 0.90-3.45]). The cholesterol outcome did not differ, and the majority of patients did not repeat lipid levels during follow-up.Risk communication and lay outreach increased cholesterol treatment discussions with primary care clinicians. However, most discussions did not result in statin prescribing. For outreach to be successful, it should be combined with interventions to encourage clinicians to follow contemporary risk-based cholesterol treatment guidelines.URL: http://www.clincialtrials.gov. Unique identifier: NCT01610609.
View details for DOI 10.1161/CIRCOUTCOMES.115.001723
View details for Web of Science ID 000364791200006
View details for PubMedID 26555123
Parenteral Nutrition Use and Associated Outcomes in a Select Cohort of Low Birth Weight Neonates
AMERICAN JOURNAL OF PERINATOLOGY
2014; 31 (11): 933-938
The aim of this study is to assess the influence of parenteral nutrition (PN) on the time to regain birth weight in premature neonates born between 1,500 and 2,499 g.A retrospective analysis stratified premature neonates born between 1,500 and 2,499 g by receipt of PN or intravenous dextrose at ≤ 72 hours of age. The primary outcome was the time to regain birth weight. Secondary measures included preterm-associated morbidities, time to achieve predefined enteral nutrition milestones, and length of stay. Multivariable regression estimated associations between PN and time to achieve nutrition milestones.Among 260 eligible neonates, those receiving PN (53%) were less mature, weighed less at birth, had a higher index of illness severity, and higher prevalence of preterm-associated morbidities (p < 0.01). The time to regain birth weight (PN, 9.4 ± 3.5 d; no PN, 9.5 ± 3.4 d) was similar between groups. Regression analysis adjusting for gestational age, illness severity, and sepsis demonstrated that PN exposure was associated with a greater time to achieve nutrition milestones and length of stay (p < 0.05).Although its impact on growth remains uncertain among premature neonates born between 1,500 and 2,499 g, PN was independently associated with a greater time to achieve nutrition milestones.
View details for DOI 10.1055/s-0033-1363770
View details for Web of Science ID 000343344800002
View details for PubMedID 24515618